After 6 weeks on CDAHFD (Figure 6A), Il18bp−/−Ifng−/− mice exhibited similar ALT levels (Figure 6B) and steatosis (Figures 6C, E) as well as similar exacerbation in liver fibrosis (Figures 6C, D) as Il18bp−/− mice when compared with WT mice. Here, IL18BP is linked to steatosis.